From a practical standpoint, individuals using GLP-1-based therapies (the approved class most pharmacologically similar to retatrutide) are increasingly advised by clinicians to: Maintain adequate dietary protein intake general guidance from sports nutrition and dietetic sources suggests approximately 1.21.6 g per kg of body weight per day for those undertaking resistance exercise, though this should be individualised with a dietitian or clinician, particularly for older adults or those with kidney disease Engage in regular resistance exercise to preserve muscle tissue Consider evidence-based supplements such as creatine, under medical supervision Whilst the specific combination of creatine and retatrutide has not been studied in clinical trials, the rationale for using creatine to support muscle preservation during weight loss is scientifically sound
Instead, set phone reminders to drink water throughout the day
European guidelines for workplace drug testing in oral fluid (EWDTS)
LC-MS/MS was performed using an Evosep LC (Evosep Biosystems) connected to a Q Exactive HF (Thermo Fisher Scientific)
PlexusDx adds this test as a $99 add-on after your first month of treatment, allowing you to make informed decisions about switching medications with confidence in your individual genetic profile
What this means: For the first time, people with early type 2 diabetes may have an oral GLP-1 option thats effective, safe, and more acceptable than injections
